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Introduction
Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disease affecting the joints, and is associated with increased morbidity and mortality [1] [2] [3] . The synovium or synovial membrane, which surrounds the joint cavity, becomes massively hypertrophied in RA. This tissue, known as pannus, can become invasive, penetrating and degrading the cartilage and bone, resulting in joint deformities, in functional deterioration and in profound disability.
The lining layer, or intima, of the synovium is normally one to three cells thick and it comprises macrophage-like cells and fibroblast-like cells [4] . This layer undergoes thickening and hypertrophy in RA, largely due to the increased recruitment of monocytes from the blood supply in the deeper layer, or subintima, of the tissue [5, 6] . Other inflammatory cells such as T cells (mainly CD45RO) and B lymphocytes migrate from the blood into the synovium and can form ectopic lymphoid follicles around blood vessels. These structures resemble the lymphoid follicles of lymph nodes. In addition, neutrophils migrate into the synovium and end up in large numbers in the synovial joint fluid. the regulation of leukocyte extravasation, angiogenesis, cytokine production, protease and extracellular matrix synthesis, vasodilation and blood vessel permeability, and antigen presentation [7] .
In RA, endothelial cells in the synovium are generally held to play a central role in the pathophysiology. The cells achieve this in several ways. First, as a component of blood vessels in the subintima, endothelial cells allow the migration of leukocytes such as T cells, B cells, monocytes, neutrophils and dendritic cells into the joint tissues and fluid. Endothelial cells undergo activation, expressing adhesion molecules and presenting chemokines, leading to leukocyte migration from the blood into the tissue. Second, the permeability of endothelial cells increases, leading to plasma extravasation, to oedema formation and to swelling of the joint [8] . Third, endothelial cells proliferate as part of the angiogenic process, which allows a supply of oxygen and nutrients to the growing pannus. There is also a net increase in the turnover of endothelial cells since the number of apoptotic endothelial cells increases as well as the number of proliferative cells [9] . Finally, endothelial cells express various cytokines, cytokine receptors and proteases that are involved in angiogenesis, in proliferation and in tissue degradation.
As part of this spectrum of biological activities, synovial endothelial cells in RA express a variety of phenotypes that can be characterised as being activated, angiogenic, apoptotic and leaky. The intent of the present review is to examine the pattern of human endothelial cell gene expression associated with these phenotypic alterations and to examine whether certain genes are selectively regulated in endothelial cells and not in other cell types. (See Table 1 for a summary of genes.)
Morphological and ultrastructural activation
Changes to the endothelium are among the first pathophysiological events that occur in the human RA synovium, and these changes occur in venules and capillaries rather than in arterioles [8, 10] . During the first month of synovitis, these changes include hypertrophy with the cells becoming cuboidal in morphology, the development of gaps between endothelial cells and the presence of multiple concentric layers in the basement membrane. Associated with these changes is the transendothelial migration of numerous mononuclear and polymorphonuclear inflammatory cells.
In another study, synovial biopsies from one patient with monoarthritis who was subsequently found to have RA showed endothelial cell proliferation with no detectable inflammatory infiltrate [8, 10] . Endothelial cell proliferation may thus be the initial event in RA. However, another study suggested that the recruitment of mononuclear cells from the blood into the perivascular areas and the lining layer occurs before endothelial morphological alteration and proliferation [11] .
The cuboidal morphology of the endothelial cells of synovial venules resembles that of high endothelial venules (HEV), which are the postcapillary venules of lymphoid tissues specialised in lymphocyte migration [12] . This change presumably represents a response to cytokines and other factors that occur in the synovial milieu, and relates to the increased leukocyte trafficking into the tissue [13] . The postcapillary venules of the rheumatoid synovium in patients with active, untreated disease exhibit HEV-like morphology, especially in regions near lymphocyte aggregates, whereas tissue samples from patients whose disease has been modified by treatment exhibit a flatter endothelium [13, 14] .
In the skin of primates, HEV-like blood vessels are induced by stimulation with tumour necrosis factor (TNF)-α and IFN-γ, which also elicit the adhesion and extravasation of inflammatory cells [15] . Other studies have shown that HEV are not absolutely necessary for transendothelial migration of T cells as migration also occurs through flat endothelium, although the transit time is considerably longer [16] . The HEV-like morphology may thus be associated with the increased leukocyte recruitment that occurs in synovial inflammation, due to the enhanced or selective presentation of chemokines and adhesion molecules, whereas the flatter endothelium may be more associated with basal leukocyte trafficking.
Many of these changes are not specific to RA, since cuboidal endothelial cells have been demonstrated in a variety of inflammatory diseases [12] . In addition, multiple concentric layers in the basement membrane of capillaries have been observed in muscle capillaries in other rheumatic diseases such as systemic lupus erythematosis and systemic sclerosis [17, 18] , and in nonrheumatic diseases such as Duchenne muscular dystrophy [19] .
Gene expression associated with leukocyte migration Adhesion molecules
As part of leukocyte migration occurring at sites of inflammation, circulating leukocytes adhere to the luminal surface of the endothelium. This interaction, according to the current paradigm, involves the sequential engagement of leukocyte and endothelial adhesion molecules. First, selectins and their carbohydrate counterligands mediate leukocyte tethering and rolling. Leukocyte integrins and their ligands on endothelial cells, including intercellular adhesion molecules (ICAMs), then mediate firm leukocyte adhesion [20] .
Endothelial cells have been shown to express a variety of adhesion molecules in the RA synovium. As a part of endothelial activation, several of these molecules are induced or upregulated by cytokines such as TNF-α, IL-1 and IFN-γ [21] . There is good evidence for the presence of selectins and their counterligands that could promote leukocyte tethering and rolling [13, 22] . E-selectin shows an endothelial-selective distribution in synovia where its expression is upregulated in RA compared with osteoarthritic (OA) tissue [23] . This adhesion molecule is a marker of endothelial activation in lymphocyte-rich regions of the RA synovium [24] . In addition, synovial endothelial cells situated in inflammatory infiltrates stain positively with the monoclonal antibody MECA-79 [25] . This antibody recognises sulphated carbohydrate structures on counterligands for L-selectin [26] , which are expressed on HEV from lymphoid and chronically inflamed tissues [12] . P-selectin has been detected on RA endothelial cells where its distribution is endothelial selective, and there is no difference in the level of expression between RA and control samples [27] .
ICAM-1 is a ligand for the β 2 integrins of leukocytes and is present on most RA synovial endothelial cells, as well as on macrophages and fibroblasts [21, 23, 28] . ICAM-1 expression is upregulated on these cell types in RA compared with normal synovium. There is also increased ICAM-1 expression on cuboidal HEV-like endothelia compared with 'flat' endothelia. ICAM-1, like E-selectin, is hence considered a marker of endothelial activation. ICAM-2, another β 2 integrin ligand, is mainly expressed on synovial endothelial cells and not by other cell types [23, 28] . However, this adhesion molecule is expressed by most RA endothelia and normal endothelia, suggesting that it is not an activation antigen on these cells. ICAM-3 has been detected on cells of myeloid origin in the synovium, but there is little or no expression of this molecule on the endothelium [28] . All three ICAMs are expressed by RA synovial dendritic cells that also harbour MHC class II antigens.
Available online http://arthritis-research.com/content/6/2/60 a In the case of soluble mediators such as cytokines, the presence of a protein within a cell does not necessarily mean that it is produced there. It may be produced elsewhere and bound and internalised by the cell of interest. b E, endothelial selective distribution, a potential marker for these cells; EO, gene expressed by endothelial and other cells in the synovium; RA < C, gene expression lesser in RA synovium than in control synovium; RA > C, gene expression greater in RA synovium than in control synovium; RA = C, gene expressed equally in RA synovium and control synovium; P, protein studied; M, mRNA studied.
Vascular cell adhesion molecule (VCAM)-1 mRNA and protein is present in the RA endothelium, albeit weakly, and is mainly expressed in lining cells and macrophages [29, 30] . The CS-1 isoform of fibronectin is expressed on the luminal surface of the endothelium and by lining layer cells in RA synovia, with less expression occurring in control synovia [22, 31, 32] . Both VCAM-1 and CS-1 fibronectin are ligands for α 4 integrins expressed by lymphocytes and monocytes, and may be functional in lymphocyte adhesion to synovial endothelial cells [33] .
CD31 (PECAM-1) is present on most synovial endothelial cells, as well as on macrophages and lining cells, and its expression on endothelia is comparable in RA and normal synovia [23, 27] . CD146 is a cell adhesion molecule that belongs to the immunoglobulin supergene family and is potentially involved in leukocyte-endothelial interactions [34] . CD146 is expressed almost exclusively by the vascular endothelium in RA synovia and in normal synovia. The high levels of soluble CD146 found in RA synovial fluid, particularly in early disease, may reflect increased endothelial activity and angiogenesis. Vascular adhesion protein-1 was originally isolated from synovial endothelial cells, and it localises selectively to endothelial cells and not to other cell types in human RA synovia [35] . Vascular adhesion protein-1 expression is increased in joint inflammation and is a marker of activated endothelium in the pig and the dog [36] . Other adhesion molecules expressed by RA synovial endothelial cells include CD44 and cadherins [13, 23, 27] .
The functional importance of adhesion molecules in human RA has been shown by the administration of antibodies in vivo. For example, anti-ICAM-1 treatment in RA patients with active disease causes a reduction in disease activity [37] 
Gene expression associated with angiogenesis
The formation of new blood vessels, termed angiogenesis, occurs in the rheumatoid synovium. It is generally accepted that angiogenesis is central to maintaining and promoting RA [7, [64] [65] [66] . The increased endothelial surface area provides the potential for enhanced leukocyte recruitment. In addition, angiogenesis is required for the formation and maintenance of the pannus since the increased volume of this invasive tissue needs a supply of oxygen and nutrients. It is proposed that angiogenesis occurs in several stages. First, at the new branch point the endothelium becomes activated by cytokines, the blood vessel permeability increases and the basement membrane is disrupted by the release of proteolytic enzymes from the endothelium. The endothelial cells then proliferate and migrate towards a chemotactic stimulus to form a new tube, and a new basement membrane is deposited. The increased permeability of the blood vessels may be mediated by proinflammatory agents, such as substance P, and results in tissue oedema. In this context, substance P receptors have been identified on endothelial cells in the RA synovium [67] .
Evidence for endothelial cell proliferation in the RA synovium is the expression of cell-cycle-associated antigens (PCNA and Ki67), the αvβ3 integrin, which is associated with vascular proliferation, and vascular endothelial growth factor (VEGF) [68, 69] . Interestingly there is an increased turnover of blood vessels in the RA synovium with focal regions of angiogenesis and vascular regression. Increased cell death in the endothelium was shown by elevated labelling of DNA fragments by terminal uridyldeoxynucleotide nick-end labelling. This occurred in the same synovial tissue samples where there was a concurrent increase in the expression of proliferative markers. These changes are related to the remodelling of the synovial vasculature, leading to reduced vascular densities adjacent to the synovial lining region and to increased vascular densities in the deeper synovium.
It should be mentioned that the vascularity of the RA synovium is the subject of ongoing discussions. One study has shown the mean number of vessels per unit volume of synovium was higher in RA than in control tissue [70] , whereas another reported that the vessel density was reduced in the RA synovium [71] . These differences may, in part, be explained by variation in sampling between these studies [72,73]. Cell adhesion molecules play a role in the regulation of angiogenesis. In addition to mediating leukocyte adhesion to the endothelium, VCAM and E-selectin potentiate angiogenesis, with the latter contributing to the morphogenesis of the capillary tube [94] . The invasion, migration and proliferation of endothelial cells during angiogenesis are also regulated by integrins [7] . These molecules are expressed at the cell surface of activated endothelial cells and interact with a large array of extracellular matrix proteins. Several integrins have been shown to be expressed by the RA endothelium [13] . These include β1 integrins, such as α4β1 and α5β1 that bind to fibronectin, and α6β1 that interacts with laminin. In addition, collagenbinding integrins are expressed by the vascular endothelium, including α2β1. αV can associate with several β chains and can have multiple specificities, including interactions with vitronectin and fibronectin. αVβ3 is expressed by several cell types including activated leukocytes and endothelial cells. It is minimally, if at all, expressed on resting or normal blood vessels but is highly expressed in RA synovial blood vessels, where it is viewed as a marker for endothelial activation [27, 69] .
Regulators of angiogenesis
The relevance of angiogenesis in the pathophysiology in RA has been shown in animal models. For example, TNP-470 (a compound that exerts antiangiogenic, as well as other, effects) was found to suppress established disease associated with a marked inhibition of pannus formation and neovascularisation in type II collagen-induced arthritis in rats [66, 95] . In addition, a soluble form of the Flt-1 VEGF receptor significantly reduces disease severity and joint destruction in murine collagen-induced arthritis [96] . In human RA, the anti-TNF antibody infliximab reduces synovial vascularity as assessed by immunostaining for CD31, von Willebrand factor and αVβ3 integrin [66] . Observations suggest that part of the beneficial effects of anti-TNF treatment in RA may be related to decreased production of VEGF and reduced angiogenesis.
Proinflammatory cytokines, other mediators and their receptors
In the RA synovium IL-1α and IL-1β are mainly secreted by macrophages, but also localise to endothelial cells and lymphocytes [97] [98] [99] . This cytokine stimulates T-cell migration into RA synovia engrafted into the SCID mouse. IL-17 is produced by the RA synovium, induces production of metalloproteinases and could activate the endothelium enhancing leukocyte extravasation [111] . In this respect, the IL-17 receptor is expressed in RA synovia, mainly on endothelial cells, where its expression is higher than in OA synovia [112] .
Elevated levels of corticotropin-releasing hormone (CRH) are produced locally in the inflamed synovium, and a role for CRH is indicated in the pathogenesis of inflammatory joint disease [113] . The CRH receptor type 1 mRNA and protein are abundantly expressed by RA synovial endothelial cells, as well as by mast cells, where this receptor may be involved in vascular permeability changes and in angiogenesis. The receptor is not expressed in normal synovia. In another study, staining for CRH receptor and the CRH ligand urocortin was demonstrated in RA endothelial cells and in a variety of other cell types [114] . Kinin levels are raised in RA and have been implicated in the pathogenesis of RA by causing release of cytokine and noncytokine mediators such as IL-1, TNF, PAF, histamine and prostaglandin E2, which contribute to joint destruction, leukocyte influx, pain, oedema and angiogenesis [115] . Kinin B2 receptors have been detected on synovial endothelial cells, on lining cells and on fibroblasts in RA and in OA samples [116] .
Midkine is a retinoic acid-inducible heparin-binding cytokine that stimulates neutrophil chemotaxis. The protein is detected on the endothelial cells and synoviocytes in inflamed synovia, and less in noninflamed tissue [117] . The protein for stem cell factor, but not its receptor (c-kit), localises to synovial endothelial cells, macrophages and fibroblasts in RA and OA synovia [118] . In addition, the somatostatin receptor (sst2a) protein localises to the RA synovial endothelium and to macrophages [119] .
Proteases
Proteases function in the degradation of the basement membrane and other regions of the extracellular matrix, playing a role in angiogenesis and enhancing leukocyte migration into the tissue [120] . Microvascular endothelial cells are also present in the invasive synovial pannus, such as at the cartilage-pannus junction [97, 99, 103, 121] . Proteases released by endothelial cells could therefore contribute to cartilage and bone destruction caused by the pannus. In this respect, however, it is not known how much of a contribution endothelial cells make compared with other cell types such as fibroblasts and macrophages.
Several proteases are produced by the RA synovial endothelium. In early RA the mRNAs for matrix metalloproteinase (MMP)-1 (collagenase) and the cysteine proteases cathepsin B and cathepsin L are expressed by synovial endothelial cells, as shown by in situ hybridisation [120] . There is only scant expression of these enzymes in normal synovia. MMP-3 (stromelysin) mRNA mainly occurs in the lining layer in RA synovia but is also expressed by endothelial cells [122] . The MMP-9 (gelatinase B) and MMP-13 (collagenase 3) proteins occur in endothelial cells, fibroblasts and leukocytes within the RA synovium, where they occur in elevated levels compared with the OA synovium [123, 124] . Membrane type 1-MMP mRNA is detected in endothelial cells and fibroblasts of RA synovia, and there is less expression of the protease in control synovia [125] . Regarding the regulation of MMP gene expression, the oncogene Ras (which upregulates MMP-1 and cathepsins) has been shown to colocalise with cathepsin L in the vessels of the RA synovium [126] .
Proteolytic joint destruction in RA is believed to be mediated, at least in part, by the plasminogen activation system. In this context the urokinase plasminogen activator receptor is expressed by RA synovial endothelial cells, occurring in higher levels compared with normal synovial endothelial cells. The receptor is also expressed by lining cells and sublining macrophages [127] . Tissue-type plasminogen activator also localises to the synovial endothelium in RA and in OA patients but not to other cell types [128] .
Other enzymes such as heparanase and plasmin are produced and secreted from endothelial cells. These enzymes may play a role in angiogenesis by releasing growth factors such as FGF, VEGF and HGF that are bound to heparan sulphate in the extracellular matrix [84, 129] .
Tissue inhibitor of metalloproteinases (TIMPs) antagonise the effects of destructive MMPs. The expression of TIMP-1 and TIMP-2 has been shown in endothelial cells and lining cells in RA synovia but not in normal synovia [130] . It has been reported that the RA synovial endothelium produces decreased amounts of TIMP [131] . This may in part contribute to an imbalance between MMPs and TIMPs in the RA joint, favouring tissue destruction.
Other genes
Prostaglandins are important mediators of acute and chronic inflammation [132] . Prostaglandin E has been localised to the synovial endothelium, to lining cells and to inflammatory cells, where expression is higher in RA than in OA tissue [133] . The production of these mediators is catalysed by an enzyme cascade that includes cyclooxygenases (COXs). There are two isoforms of COX expressed in the synovium. COX-2 localises to endothelial cells, to mononuclear leukocytes and to fibroblasts, and COX-2 expression is increased in inflammatory arthritis compared with in noninflammatory arthritis [132] . COX-1, in contrast, is constitutively expressed, particularly by lining cells, and there is no difference in immunostaining between inflammatory and noninflammatory arthritis.
Another enzyme involved in prostaglandin synthesis is phospholipase A2. In this context, phospholipase A2 activating protein has been shown to be present in a variety of cells in the RA synovium, including endothelial cells, vascular smooth muscle and monocytes/macrophages [134] .
Nitric oxide is synthesised by the action of a family of nitric oxide synthases, which are either constitutive or inducible. The production of nitric oxide plays a role in inflammation and physiological processes [135] . The expression of inducible nitric oxide synthase protein and mRNA has been shown in RA synovia, localising to the endothelium, to macrophage-like lining cells and, to a lesser extent, to fibroblasts [136] . There is only minimal labelling of these cells in normal synovium. Recent data suggest that nitric oxide production by inducible nitric oxide synthase has anti-inflammatory effects in experimental arthritis by mediating a reduction in leukocyte adhesion and infiltration [137] .
Enhanced expression of activation markers, such as the protooncogene c-fos, has been reported in RA synovial endothelium compared with OA synovial endothelium [138] . The pentaxin PTX3 has a structure related to Creactive protein and may play a role in inflammatory circuits in RA. PTX3 is expressed by the endothelium and synoviocytes in RA synovia [139] . Annexins are calciumbinding proteins with diverse functions including regulating inflammation and may have an intracellular role as cytoskeletal elements in exocytosis and cell differentiation. Endothelial cells in the RA synovium stain strongly for annexin IV and annexin VI, and weakly for annexin I and annexin II [140] . Lymphoid cells are also strongly positive for annexin VI in the RA synovium.
Conclusions
This review has reported 76 genes expressed by or on the synovial endothelium in the RA synovium (Table 1 ). Of these, 13 genes showed a preferential endothelial distribution and could be considered potential markers of these cells. In addition, 29 out of the reported 76 genes showed increased expression in the RA endothelium in comparison with non-RA control endothelial cells, and such genes may be implicated in the pathophysiology of RA. Future studies of these genes and other pathways specifically induced in RA endothelial cells may lead to the development of novel endothelium-targeted therapies for RA and to other forms of inflammatory arthritis.
